[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From The JAMA Web Sites
June 16, 1999

A New Source of Resistance to HIV Drugs

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(23):2186-2187. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-23-jac90005

In Reply: In response to Dr Harris and colleagues, our article was not intended to provide a complete review of the state of the art in the management of and research about glaucoma. We fully recognize the fascinating and significant work that is being done, not only in the field of ocular circulation but in many other aspects of the study of glaucoma. Agents that improve optic nerve blood flow may well become part of the armamentarium in the management of this disease. However, the past 10 years have seen the release and widespread clinical use of many new antiglaucoma agents, such as prostaglandins, clonidine derivatives, topical carbonic anhydrase inhibitors, and novel preparations of topical β-blockers. Newer optic nerve imaging and visual-field technologies have been developed, allowing for more accurate and earlier diagnoses. Major breakthroughs have been made in our understanding of the genetics of glaucoma, discoveries that may someday lead to a cure. The pace of development in glaucoma research is heartening, given the severity and incidence of the disease.

First Page Preview View Large
First page PDF preview
First page PDF preview
×